Biosimilars saved the
European healthcare
systems over €30
since 20121.
Biocon Biologics is proud to lead the way in the advancement of biosimilars. As we continue to drive innovation and invest in the future, our mission is singularly focused on the development, manufacturing, distribution, and commercialization of high quality biosimilars in the world.
  • ~4.5 billion treatment days provided to European patients since launch1
  • +13% patient treatment days were attributed to biosimilars in 20221*

*2022 over 2021
‡ 2012 – 2022 cumulative savings at list prices from the impact of biosimilar competition in Europe. List prices across Europe act as a base-case to estimate savings generated in European markets.
1. IQVIA, White Paper. The Impact of Biosimilar Competition in Europe. December 2022


A fully integrated global biosimilars company, all in on biosimilars.

  • A unique biosimilars portfolio spanning from insulins to recombinant proteins, and monoclonal antibodies
  • Cutting-edge science and research capabilities
  • Experience built from successful global partnership with Mylan/Viatris
  • Global-scale manufacturing with high standards of quality and compliance

20+ biosimilars

approved or in development

8 biosimilars

launched across global markets

100+ countries

where Biocon Biologics’ biosimilars are available

5.7M patients served

globally by Biocon Biologics’ biosimilars

A long-standing presence
in the biosimilars industry
Biocon Biologics has emerged as a leading biosimilars player in Europe and worldwide, providing innovative and more affordable ways to treat diabetes, cancer, and autoimmune diseases. As a result of its successful global partnership with Viatris, Biocon Biologics has broadened its biosimilars capability from lab to market, commercializing the products it has been manufacturing for years.
offerings with a focus
on the future.
With a unique portfolio of monoclonal antibodies and insulins, Biocon Biologics is fully committed to the long-term sustainability of global biosimilars access, investing more than $1 billion in R&D and global-scale manufacturing over the last 2 decades.
Biocon Biologics has 20 biosimilar assets in the pipeline, including insulins and monoclonal antibodies spanning therapy areas such as:
Biocon Biologics: an integrated player with proven end-to-end expertise
Research and Innovation
Product Development
Clinical Trials
Global-scale Manufacturing
Regulatory Sciences

Our ongoing efforts continue to expand affordable access to biosimilars for patients worldwide